Format

Send to

Choose Destination
Genes Cancer. 2017 Mar;8(3-4):497-504. doi: 10.18632/genesandcancer.136.

NSCLC depend upon YAP expression and nuclear localization after acquiring resistance to EGFR inhibitors.

Author information

1
Department of Cancer Genetics, Radium Hospital - Oslo University Hospital, Oslo, Norway.
2
Department of Pathology, Oslo University Hospital, Oslo, Norway.
3
Institute for Clinical Medicine, Faculty of Medicine, University of Oslo, Norway.
4
Section of Oncology, Drammen Hospital, Vestre Viken Hospital Trust, Drammen, Norway.

Abstract

Yes-associated protein (YAP) is a downstream target of the Hippo pathway and has been found to be oncogenic driving many cancers into developing metastatic phenotypes leading to poor survival outcomes. This study investigated if YAP expression is associated with drug resistance in two non-small cell lung cancer (NSCLC) lines (HCC827 and H1975) generated to become resistant to the EGFR tyrosine kinase inhibitors (EGFR TKI) erlotinib, gefitinib or the T790M-specific osimertinib. We found that acquired EGFR TKI resistance was associated with YAP over-expression (osimertinib-resistant cells) or YAP amplification (erlotinib- and gefitinib-resistant cells) along with EMT phenotypic changes. YAP was localized in the nucleus, indicative of active protein. siRNA-mediated silencing of YAP resulted in re-sensitizing the drug-resistant cells to EGFR TKI compared to the negative siRNA controls (p = <0.05). These results suggest YAP is a potential mechanism of EGFR-TKI resistance in NSCLC and may presents itself as a viable therapeutic target.

KEYWORDS:

Drug-resistance; EGFR; EMT; NSCLC; YAP

Supplemental Content

Full text links

Icon for Impact Journals, LLC Icon for PubMed Central
Loading ...
Support Center